# Phase III Trial of VDJ001 In Patients With Moderate-to-severe Active Rheumatoid Arthritis

> **NCT06726096** · PHASE3 · ENROLLING_BY_INVITATION · sponsor: **Beijing VDJBio Co., LTD.** · enrollment: 615 (estimated)

## Conditions studied

- Rheumatoid Arthritis (RA)
- Anti IL-6R

## Interventions

- **BIOLOGICAL:** Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection

## Key facts

- **NCT ID:** NCT06726096
- **Lead sponsor:** Beijing VDJBio Co., LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2025-04-09
- **Primary completion:** 2026-04-20
- **Final completion:** 2026-12-31
- **Target enrollment:** 615 (ESTIMATED)
- **Last updated:** 2025-08-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06726096

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06726096, "Phase III Trial of VDJ001 In Patients With Moderate-to-severe Active Rheumatoid Arthritis". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT06726096. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*